{"page":{"totalFilteredElements":25},"studies":[{"active":true,"description":"Patienten-Typologisierung f&#252;r ein bedarfsgerechtes und effektiveres Coaching bei Patientinnen mit Hormonrezeptor positiven MammaCa / PaTyp<div><br /></div><div><b>VERSORGUNGSFORSCHUNGSSTUDIE</b></div>","eudractNumber":null,"id":10616,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"ER (Östrogenrezeptor)","id":"mt_248"}],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-03-13T08:39:41+01:00","shortTitle":"PaTyp","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Onko Coaching und fr&#252;he Palliative Begleitung als patientenzentrierte Versorgungselemente in der Therapie nicht heilbarer Krebserkrankungen &#8211; OnCoPaTh<div><b>VERSORGUNGSFORSCHUNGSSTUDIE</b><br /></div>","eudractNumber":null,"id":6548,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2021-02-18T11:32:43+01:00","shortTitle":"Patientencoaching OncoPath","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A&#160;Retrospective, Multicountry Study of Clinical Outcomes in Patients with Relapsed/ Refractory Multiple Myeloma Treated with T-cell Redirectors Outside of Clinical Trials (REALiTEC)<br /><div>\n  64007957MMY4004\n  [REALiTEC]</div>","eudractNumber":null,"id":8882,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06285318","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-05-01T13:07:26+02:00","shortTitle":"REALiTEC","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Simultan integrierter Boost in der HNO Quality Control Registry","eudractNumber":null,"id":2554,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06831903","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2019-10-01T13:37:34+02:00","shortTitle":"Register SIB HNO","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"SURVIVE (Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer) - a partially double-blinded, multicenter, randomized, controlled superiority study<div><br /></div><div>DRKS00030745<br /></div>","eudractNumber":null,"id":9451,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05658172","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-03-25T14:04:07+01:00","shortTitle":"SURVIVE","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]}]}